Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
Q4 2025 vs. Q3 2025
How the institutions holding Esperion Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 189 | 3 | 201 | +15 |
| Shares | 108.0M | 60.0K | 151.3M | +43.4M (+40.2%) |
| Value | $286.1M | $159.0K | $559.6M | +$273.7M (+95.7%) |
3 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (43)
Institutions that held Esperion Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (28)
Institutions that held Esperion Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
Not filed for Q4 2025 yet (3)
Institutions that held Esperion Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Point72 (DIFC) Ltd | 31,989 | $84.8K |
| CIBC Bancorp USA Inc. | 21,286 | $56.4K |
| Point72 Europe (London) LLP | 6,719 | $17.8K |